KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Liabilities (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 78.34% to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, up 78.34% year-over-year, with the annual reading at $6.1 million for FY2025, 78.34% up from the prior year.
  • Other Non-Current Liabilities hit $6.1 million in Q4 2025 for CRISPR Therapeutics AG, up from $5.3 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $8.7 million in Q2 2021 to a low of $958000.0 in Q4 2023.
  • Historically, Other Non-Current Liabilities has averaged $5.4 million across 5 years, with a median of $5.4 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 83.95% in 2023 and later soared 259.5% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $7.3 million in 2021, then dropped by 18.67% to $6.0 million in 2022, then tumbled by 83.95% to $958000.0 in 2023, then skyrocketed by 259.5% to $3.4 million in 2024, then surged by 78.34% to $6.1 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CRSP at $6.1 million in Q4 2025, $5.3 million in Q3 2025, and $4.5 million in Q2 2025.